Clinical Trials

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations


Study ID
Alliance A071401

NCT Number
NCT02523014 (Click on the NCT number for more information about the trial)

Research Study Number
00006148

Principle Investigator
Dr. Samuel Goldlust

Phase
II

Sponsor
Alliance


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now